ClinicalTrials.gg
RecruitingNCT06737731Updated Jan 9, 2026

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of SHR-1681 in Malignant Solid Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.

02

Conditions studied

  • Malignant Solid Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form;
  2. Subjects with or cytologically confirmed unresectable locally advanced or solid tumors which is to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently;
  3. Have at least one measurable tumor lesion per v1.1;
  4. performance score of 0-1;
  5. ≥ 3 months;
  6. Adequate bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with active central nervous system or meningeal metastases;
  2. History of serious cardiovascular and cerebrovascular diseases;
  3. Subjects with a history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis;
  4. Severe infection within 4 weeks prior to the first dose;
  5. Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of study drug;
  6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per v5.0.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SHR-1681

    Drug: SHR-1681

Interventions

  • DrugSHR-1681

    SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Time frame: 12 months.

  2. Maximum administered dose (MAD)

    Time frame: 12 months.

  3. Recommended Phase 2 dose (RP2D)

    Time frame: 12 months.

  4. Incidence and severity of adverse events (AEs)

    Time frame: Approximately 3 years.

  5. Incidence and severity of serious adverse events (SAEs)

    Time frame: Approximately 3 years.

Secondary outcomes

  1. Time to maximum concentration (Tmax) of SHR-1681

    Time frame: Approximately 3 years.

  2. Maximum concentration (Cmax) of SHR-1681

    Time frame: Approximately 3 years.

  3. Area under the concentration-time curve from time 0 to the last measurable concentration time point (AUC0-t) of SHR-1681

    Time frame: Approximately 3 years.

  4. Area under the concentration-time curve from time 0 to infinity (AUC0-∞) of SHR-1681

    Time frame: Approximately 3 years.

  5. Anti-SHR-1681 antibody (ADA) of SHR-1681

    Time frame: Approximately 3 years.

  6. Overall response rate (ORR)

    Time frame: Approximately 3 years.

  7. Duration of response (DoR)

    Time frame: Approximately 3 years.

  8. Disease control rate (DCR)

    Time frame: Approximately 3 years.

  9. Progression-free survival (PFS)

    Time frame: Approximately 3 years.

  10. Overall survival (OS)

    Time frame: Approximately up to 5 years after the last subject enrolled.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Nov 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 17, 2024
StartActual
Jan 21, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Jul 2027
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06737731
Responsible party
Sponsor
First posted
Dec 17, 2024
Start date
Jan 21, 2025
Primary completion
Nov 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Fei Qiu
Contact
fei.qiu@hengrui.com
+86-0518-82342973
Ting Lu, M.M
Contact
ting.lu@hengrui.com
+86-18825721498

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion